EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access

Early-Phase Oral Antiviral Use and Post–COVID-19 Condition in Outpatients

Makoto Hibino, Ayumi Shintani, Hiroyuki Murayama, Nobuyuki Morikawa, Kazunari Maeda, Sho Nishiguchi, Eiji Monma, Hiromasa Harada, Tsunekazu Takagi, Satoshi Kuroyanagi, Kiyoshi Endo, Yasushi Terada und 4 weitere

JAMA Network Open · 15.05.2026 · 9 (5) · e2611983

DOI: 10.1001/jamanetworkopen.2026.11983 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Network Open, online erschienen am 15.05.2026. Verfasst von Makoto Hibino und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Shonan Oiso Hospital, Kanagawa, Japan. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19, COVID-19 Drug Treatment. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Post–COVID-19 condition (PCC) contributes substantially to long-term morbidity after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Information about the effectiveness of oral antivirals in preventing PCC in outpatient populations remains limited.

Objective

To evaluate the association between early oral antiviral use and PCC risk among outpatients with COVID-19, with and without risk factors for severe disease. Design, Setting, and Participants Prospective, nationwide, multicenter, registry-based cohort study conducted at 51 acute-care hospitals across Japan during the predominance of Omicron sublineages JN.1 and KP.3. Outpatients aged 12 years or older with laboratory-confirmed COVID-19, symptom onset of 5 days or less before enrollment, and no recent anti–SARS-CoV-2 treatment were enrolled between February and October 2024, with follow-up through February 2025. The primary analysis population included participants with complete baseline covariates and valid day 28 and day 84 assessments. Exposures Oral antiviral use (ensitrelvir, nirmatrelvir, or molnupiravir) at enrollment vs no antiviral use. Main Outcomes and Measures The primary outcome was PCC, defined as persistence of 1 or more of 5 prespecified symptoms (cough, shortness of breath, malaise, smell disorder, or taste disorder), with the same symptoms reported on both days 28 and 84. Exploratory outcomes included failure to return to usual health by day 84.

Results

Among 7699 participants (2181 receiving antivirals: 1131 [51.9%] male; median [IQR] age, 58.0 [41-71] years; and 5518 without antivirals: 2928 [53.1%] female; median [IQR] age, 45.0 [29-57] years), most had mild COVID-19 (7599 participants [98.7%]) and received 2 or more vaccine doses (6902 participants [89.6%]). Participants receiving antivirals were older and had more comorbidities; other baseline characteristics were similar between groups. After prespecified adjustment, antiviral use was associated with a lower risk of PCC (adjusted risk ratio [aRR], 0.86; 95% CI, 0.78-0.93). Results were consistent for ensitrelvir (aRR, 0.86; 95% CI, 0.79-0.95) and molnupiravir (aRR, 0.81; 95% CI, 0.67-0.98). Failure to return to usual health by day 84 was less common among participants receiving antivirals than among participants without antivirals (9.9% vs 12.9%; aRR, 0.77; 95% CI, 0.67-0.89). Conclusions and Relevance In this cohort study of outpatients with COVID-19, early oral antiviral use was associated with a lower risk of PCC. These findings suggest that early antiviral treatment may help mitigate long-term consequences of SARS-CoV-2 infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCOVID-19COVID-19 Drug TreatmentAdultAgedFemaleHumansMaleMiddle AgedAdministration, OralHydroxylaminesIndolesJapanOutpatientsPost-Acute COVID-19 SyndromeProlineProspective StudiesSARS-CoV-2CytidineSulfides

Substanzen

Antiviral AgentsHydroxylaminesIndolesmolnupiravirProlineumifenovirCytidineSulfides

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Shonan Oiso Hospital, Kanagawa, Japan.
  • Department of Respiratory Medicine, Shonan Fujisawa Tokushukai Hospital, Kanagawa, Japan.
  • Department of Medical Statistics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
  • Surgical Department, Narita Tomisato Tokushukai Hospital, Chiba, Japan.
  • Department of Internal Medicine, Tokyo Nishi Tokushukai Hospital, Tokyo, Japan.
  • Department of General Internal Medicine, Shonan Kamakura General Hospital, Kanagawa, Japan.

Zitieren

APA

Hibino, M., Shintani, A., Murayama, H., Morikawa, N., Maeda, K., Nishiguchi, S., Monma, E., Harada, H., Takagi, T., Kuroyanagi, S., Endo, K., Terada, Y., Kinoshita, M., Yoden, T., Miyazawa, S., & Higashiue, S. (2026). Early-Phase Oral Antiviral Use and Post–COVID-19 Condition in Outpatients. JAMA Network Open, 9(5), e2611983. https://doi.org/10.1001/jamanetworkopen.2026.11983

Vancouver

Hibino M, Shintani A, Murayama H, Morikawa N, Maeda K, Nishiguchi S, et al. Early-Phase Oral Antiviral Use and Post–COVID-19 Condition in Outpatients. JAMA Network Open. 2026;9(5):e2611983. doi:10.1001/jamanetworkopen.2026.11983

BibTeX
@article{Hibino2026,
  author = {Hibino, Makoto and Shintani, Ayumi and Murayama, Hiroyuki and Morikawa, Nobuyuki and Maeda, Kazunari and Nishiguchi, Sho and Monma, Eiji and Harada, Hiromasa and Takagi, Tsunekazu and Kuroyanagi, Satoshi and Endo, Kiyoshi and Terada, Yasushi and Kinoshita, Masahiro and Yoden, Takahiro and Miyazawa, Shogo and Higashiue, Shinichi},
  title = {Early-Phase Oral Antiviral Use and Post–COVID-19 Condition in Outpatients},
  journal = {JAMA Network Open},
  year = {2026},
  volume = {9},
  number = {5},
  pages = {e2611983},
  doi = {10.1001/jamanetworkopen.2026.11983}
}
Kostenlos starten →